Ceva is currently ranked in 3rd place globally for poultry vaccines manufacturers (2009) & number one on IBD vaccines. For years, research and development efforts, in USA and in Europe, have been focused on technology breakthroughs and innovative products such as:
-Vector vaccines: Making available the largest range of vector vaccines based on FP or HVT vector, with its lines of VECTORMUNE® FP and VECTORMUNE® HVT.
-Immune complex vaccine: With the worldwide known, CEVAC® Transmune IBD, vaccine allowing the full control IBD from the hatchery and avoiding farm vaccination.
-Live attenuated vaccines: With a large number of carefully selected live attenuated strains for IBD, ND, IB, CAV, Salmonella and Mycoplasma control.
-Killed adjuvated vaccines: With a complete range of inactivated oily or aluminium hydroxide adjuvated vaccines against IBD (Classical or Variant), ND, Avian Influenza, IB, EDS, Reovirus, Salmonella, Coryza or Pasteurella in chicken.
Ceva commitment to the poultry health sector can be summarised in the 3 values of the company:
> Entrepreneurial spirit, being closer to our partners helping them to succeed in their ambitions.
> Innovation, through new vaccination approaches: technology products and services.
> Solidarity, establishing more effective organizational ways of team working.
Poultry Biology expertise is now gathered in 5 R&D and Production centres located in:
> CEVA PHYLAXIA - Budapest (HUNGARY)
> CEVA BIOMUNE - Lenexa (Kansas - USA)
> CEVA CUERNAVACA - Cuernavaca (MEXICO)
> CEVA CAMPINAS - Campinas (BRAZIL)
> CEVA JAPAN - Yokohama (JAPAN)